Market Research Report
Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||907875|
|Published||Content info||157 Pages
Delivery time: 1-2 business days
|Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023|
|Published: August 21, 2019||Content info: 157 Pages||
Technavio's overactive bladder (OAB) therapeutics market analysis considers sales from anticholinergics. Beta-3 adrenergic agonists, and other OAB therapeutics. Our analysis also considers the sales of overactive bladder therapeutics in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing availability of branded drugs and rise in popularity of combination therapy will play a significant role in the anticholinergics segment to maintain its market position. Also, our global overactive bladder therapeutics market report looks at factors such as the increasing number of drug approvals, the advent of combination therapy, and strategic alliance. However, extensive use devices to treat OAB, side effects associated with OAB, and rising patent litigations may hamper the growth of the overactive bladder therapeutics industry over the forecast period.
The launch of combination therapy offers patients an efficacious pharmacological regime which requires shorter duration for treatment and reduces the overall cost associated with medication treatment. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. This advent of combination therapy will lead to the expansion of the global overactive bladder therapeutics market at a CAGR of almost 2% during the forecast period.
The treatment therapy available for OAB involves the use of small molecules, which helps in the relaxation of smooth muscles in the urinary bladder to control the emptying of the bladder. The medication therapy, which is used exerts its pharmacological effect by suppressing the overactivity of the detrusor muscle. The drugs used in the therapy are associated with certain side effects like dry mouth, constipation, blurred vision, and cognitive impairment. Thus, there is a need for the development of biological drugs targeting the gene and consequently improving bladder functioning. The ongoing research in this area is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global overactive bladder therapeutics market during the forecast period 2019-2023, view our report.
With the presence of several major players, the global overactive bladder therapeutics market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position. This report provides a detailed analysis of several leading overactive bladder therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Camber Pharmaceuticals Inc., Endo International Plc., KYORIN Holdings Inc., Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.